Report cover image

Europe Ophthalmic Drugs Market Forecast 2023-2032

Publisher Inkwood Research
Published Nov 17, 2023
Length 166 Pages
SKU # INKR18381621

Description

Europe Ophthalmic Drugs Market Forecast 2023-2032



KEY FINDINGS

The Europe ophthalmic drugs market is expected to register a CAGR of 5.70% during the forecast period, 2023-2032. European pharmaceutical firms make substantial investments in research and development to create innovative ophthalmic drugs and therapies, aimed at meeting unfulfilled medical requirements and broadening the market.

MARKET INSIGHTS

Belgium, Spain, Poland, Italy, the United Kingdom, France, Germany, and Rest of Europe are assessed for the Europe ophthalmic drugs market growth analysis. The German ophthalmic drugs market plays a crucial role in the nation's healthcare sector, spurred by various factors. A key driver is the increasing prevalence of eye disorders, primarily attributed to the aging population. Germany, akin to many developed nations, is experiencing a rise in age-related eye conditions such as cataracts and age-related macular degeneration, necessitating the utilization of ophthalmic drugs for treatment and management.

Another contributing factor to the German ophthalmic drugs market is the progress in drug therapies and delivery methods. These advancements have resulted in more effective and patient-friendly treatment options for eye disorders. In Germany, patients benefit from state-of-the-art drug delivery technologies, fueling the growing demand for ophthalmic drugs.

Despite these favorable aspects, the market encounters challenges. Stringent regulatory approval processes, crucial for ensuring patient safety, can lead to delays in introducing new ophthalmic medications to the market. This robust regulatory environment aims to guarantee the safety and efficacy of these drugs, upholding high standards of patient care.

COMPETITIVE INSIGHTS

Novartis AG, Thea Pharma Inc, Pfizer Inc, etc., are among the leading companies in the market.

Our report offerings include:
  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments


      • Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

166 Pages
1. Research Scope & Methodology
1.1. Study Objectives
1.2. Methodology
1.3. Assumptions & Limitations
2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
2.3. Scope Of Study
2.4. Crisis Scenario Analysis
2.4.1. Impact Of Covid-19 On Ophthalmic Drugs Market
2.5. Major Market Findings
2.5.1. Emerging Therapies For Dry Eye Syndrome
2.5.2. Growing Demand For Combination Therapies
2.5.3. Increasing Investment In Research & Development
2.5.4. Shift Toward Over-the-counter (Otc) Products
3. Market Dynamics
3.1. Key Drivers
3.1.1. Aging Population's Susceptibility To Age-related Eye Conditions
3.1.2. Advancements In Drug Delivery Technologies
3.1.3. Rising Prevalence Of Eye Diseases And Disorders
3.1.4. Favorable Reimbursement Policies By Healthcare Systems
3.2. Key Restraints
3.2.1. Delay In Drug Approvals
3.2.2. Side Effects Related To Ophthalmic Drugs
4. Key Analytics
4.1. Key Market Trends
4.2. Technology Snapshot
4.2.1. Biologics
4.2.2. Cell Therapy
4.2.3. Gene Therapy
4.2.4. Drug Delivery
4.2.5. Small Molecule
4.2.6. Other Technologies
4.3. Porter's Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Growth Prospect Mapping
4.5. Market Maturity Analysis
4.6. Market Concentration Analysis
4.7. Key Buying Criteria
4.8. Regulatory Framework
5. Market By Indication
5.1. Dry Eye
5.2. Glaucoma
5.3. Infection/Inflammation/Allergies
5.4. Retinal Disorder
5.4.1. Wet Age-related Macular Degeneration
5.4.2. Dry Age-related Macular Degeneration
5.4.3. Diabetic Retinopathy
5.4.4. Other Retinal Disorders
5.5. Other Indications
6. Market By Type
6.1. Prescription Drugs
6.2. Over-the-counter Drugs
7. Market By Dosage Form
7.1. Gels
7.2. Eye Solutions & Suspensions
7.3. Capsules & Tablets
7.4. Eye Drops
7.5. Ointments
8. Market By Therapeutic Class
8.1. Anti-glaucoma
8.2. Anti-infection
8.3. Anti-inflammatory
8.4. Anti-allergy
8.5. Other Therapeutic Classes
9. Market By Distribution Channel
9.1. Hospital Pharmacies
9.2. Drug Stores
9.3. Online Pharmacies
9.4. Other Distribution Channels
10. Geographical Analysis
10.1. Europe
10.1.1. Market Size & Estimates
10.1.2. Europe Ophthalmic Drugs Market Drivers
10.1.3. Europe Ophthalmic Drugs Market Challenges
10.1.4. Key Players In Europe Ophthalmic Drugs Market
10.1.5. Country Analysis
10.1.5.1. United Kingdom
10.1.5.1.1. United Kingdom Ophthalmic Drugs Market Size & Opportunities
10.1.5.2. Germany
10.1.5.2.1. Germany Ophthalmic Drugs Market Size & Opportunities
10.1.5.3. France
10.1.5.3.1. France Ophthalmic Drugs Market Size & Opportunities
10.1.5.4. Italy
10.1.5.4.1. Italy Ophthalmic Drugs Market Size & Opportunities
10.1.5.5. Spain
10.1.5.5.1. Spain Ophthalmic Drugs Market Size & Opportunities
10.1.5.6. Belgium
10.1.5.6.1. Belgium Ophthalmic Drugs Market Size & Opportunities
10.1.5.7. Poland
10.1.5.7.1. Poland Ophthalmic Drugs Market Size & Opportunities
10.1.5.8. Rest Of Europe
10.1.5.8.1. Rest Of Europe Ophthalmic Drugs Market Size & Opportunities
11. Competitive Landscape
11.1. Key Strategic Developments
11.1.1. Mergers & Acquisitions
11.1.2. Product Launches & Developments
11.1.3. Partnerships & Agreements
11.2. Company Profiles
11.2.1. Abbvie Inc
11.2.1.1. Company Overview
11.2.1.2. Products & Services
11.2.1.3. Strengths & Challenges
11.2.2. Accutome Inc
11.2.2.1. Company Overview
11.2.2.2. Products & Services
11.2.2.3. Strengths & Challenges
11.2.3. Bausch Health Companies Inc
11.2.3.1. Company Overview
11.2.3.2. Products & Services
11.2.3.3. Strengths & Challenges
11.2.4. Genentech Inc
11.2.4.1. Company Overview
11.2.4.2. Products & Services
11.2.4.3. Strengths & Challenges
11.2.5. Johnson & Johnson
11.2.5.1. Company Overview
11.2.5.2. Products & Services
11.2.5.3. Strengths & Challenges
11.2.6. Thea Pharma Inc
11.2.6.1. Company Overview
11.2.6.2. Products & Services
11.2.6.3. Strengths & Challenges
11.2.7. Novartis Ag
11.2.7.1. Company Overview
11.2.7.2. Products & Services
11.2.7.3. Strengths & Challenges
11.2.8. Pfizer Inc
11.2.8.1. Company Overview
11.2.8.2. Products & Services
11.2.8.3. Strengths & Challenges
11.2.9. Regeneron Pharmaceuticals Inc
11.2.9.1. Company Overview
11.2.9.2. Products & Services
11.2.9.3. Strengths & Challenges
11.2.10. Santen Pharmaceutical Co Ltd
11.2.10.1. Company Overview
11.2.10.2. Products & Services
11.2.10.3. Strengths & Challenges
11.2.11. Sun Pharmaceutical Industries Ltd
11.2.11.1. Company Overview
11.2.11.2. Products & Services
11.2.11.3. Strengths & Challenges
11.2.12. Teva Pharmaceuticals Industries Ltd
11.2.12.1. Company Overview
11.2.12.2. Products & Services
11.2.12.3. Strengths & Challenges

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us